Bob Lutz PhD

Bob is Chief Development Officer of Formation Biologics and brings extensive experience in the development of antibody-based therapeutics. Prior to joining Formation Biologics, Bob held various R&D roles over a 23 year span at ImmunoGen, Inc, where most recently he was Vice President of Translational Research and Development, with responsibility for all early stage antibody drug conjugate (ADC) development programs. In addition, Bob was a member of ImmunoGen’s portfolio research committee, served on numerous alliance committees supporting the R&D programs of ImmunoGen’s licensed partners, and was ImmunoGen’s research lead on Genentech’s trastuzumab emtansine program. Earlier, Bob was part of ImmunoGen’s Apoptosis Technology Inc subsidiary where he led the research collaboration leading to the discovery of the BH3 domain of the BCl-2 family of death regulatory proteins.